Javascript must be enabled to continue!
ATP6V0A1 protects dopaminergic neurons via the autophagy-lysosomal pathway in Parkinson’s disease
View through CrossRef
Abstract
Parkinson’s disease is the second most common neurodegenerative disorder. ATPase H+ transporting V0 subunit A1 (ATP6V0A1) is a component of vacuolar H+-ATPase (V-ATPase), an ATP-dependent proton pump. Our previous research identified an association between the ATP6V0A1 rs601999 variant and Parkinson’s disease; however, the underlying mechanisms of ATP6V0A1 in Parkinson’s disease remain elusive. In this study, we generated ATP6V0A1 knockdown and overexpression models and then examined the degeneration of dopaminergic neurons, lysosomal function, and the autophagy-lysosomal pathway using immunohistochemistry, western blotting, and transmission electron microscopy. We found that ATP6V0A1 protected against lysosomal dysfunction, regulated autophagic flux, and decreased phosphorylated α-synuclein levels in vitro. In vivo, ATP6V0A1 reduced levels of α-synuclein and phosphorylated α-synuclein proteins, mitigated degeneration of dopaminergic neurons, and improved motor dysfunction. Collectively, these findings show that ATP6V0A1 plays a protective role in Parkinson’s disease by modulating the autophagy-lysosomal pathway. A correlation between ATP6V0A1 and Parkinson’s disease susceptibility may serve as a biomarker for Parkinson’s disease, while the protective effects of ATP6V0A1 could represent a potential therapeutic target for the disease.
Ovid Technologies (Wolters Kluwer Health)
Title: ATP6V0A1 protects dopaminergic neurons via the autophagy-lysosomal pathway in Parkinson’s disease
Description:
Abstract
Parkinson’s disease is the second most common neurodegenerative disorder.
ATPase H+ transporting V0 subunit A1 (ATP6V0A1) is a component of vacuolar H+-ATPase (V-ATPase), an ATP-dependent proton pump.
Our previous research identified an association between the ATP6V0A1 rs601999 variant and Parkinson’s disease; however, the underlying mechanisms of ATP6V0A1 in Parkinson’s disease remain elusive.
In this study, we generated ATP6V0A1 knockdown and overexpression models and then examined the degeneration of dopaminergic neurons, lysosomal function, and the autophagy-lysosomal pathway using immunohistochemistry, western blotting, and transmission electron microscopy.
We found that ATP6V0A1 protected against lysosomal dysfunction, regulated autophagic flux, and decreased phosphorylated α-synuclein levels in vitro.
In vivo, ATP6V0A1 reduced levels of α-synuclein and phosphorylated α-synuclein proteins, mitigated degeneration of dopaminergic neurons, and improved motor dysfunction.
Collectively, these findings show that ATP6V0A1 plays a protective role in Parkinson’s disease by modulating the autophagy-lysosomal pathway.
A correlation between ATP6V0A1 and Parkinson’s disease susceptibility may serve as a biomarker for Parkinson’s disease, while the protective effects of ATP6V0A1 could represent a potential therapeutic target for the disease.
Related Results
Arousal-State Dependent Alterations in VTA-GABAergic Neural Activity
Arousal-State Dependent Alterations in VTA-GABAergic Neural Activity
AbstractDecades of research have implicated the ventral tegmental area (VTA) in motivation, reinforcement learning and reward processing. We and others recently demonstrated that i...
Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract
Considering that a tumor promoting role for GSK3 has been suggested in pancreatic cancer (PC) cells and that GSK3 inhibitors are currently under clinical tr...
A Mechanism Study on the Antioxidant Pathway of Keap1-Nrf2- ARE Inhibiting Ferroptosis in Dopaminergic Neurons
A Mechanism Study on the Antioxidant Pathway of Keap1-Nrf2- ARE Inhibiting Ferroptosis in Dopaminergic Neurons
Background:
The pathology of Parkinson's disease (PD) indicates that iron deposition
exists in dopaminergic neurons, which may be related to the death of cellular lipid iron peroxi...
Data from Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
Data from Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
<div>Abstract<p>Autophagy is a mechanism by which cells degrade cellular material to provide nutrients and energy for survival during stress. The autophagy is thought t...
Data from Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
Data from Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
<div>Abstract<p>Autophagy is a mechanism by which cells degrade cellular material to provide nutrients and energy for survival during stress. The autophagy is thought t...
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease
AbstractAlpha melanocyte-stimulating hormone (α-MSH) is an autocrine factor released by activated microglia during neuroinflammation and is elevated in the cerebrospinal fluid of P...
Abstract 2271: Autophagy induction by low dose cisplatin: The role of p53 in autophagy
Abstract 2271: Autophagy induction by low dose cisplatin: The role of p53 in autophagy
Abstract
Cisplatin has been mainly used for lung-cancer. However, cisplatin has many side effects, so the usage of cisplatin has a limitation. Recently, autophagy ha...
Cytotoxicity of arginine deprivation to AML cells is mediated by autophagy / by Fatima Taki . (c2020)
Cytotoxicity of arginine deprivation to AML cells is mediated by autophagy / by Fatima Taki . (c2020)
In this study, we assess the activation of autophagy in AML cells following arginine deprivation, the mechanism of its activation, and its impact on cell cytotoxicity. Arginine dep...

